MSF sent this open letter to the CEO of ViiV Healthcare, urging the company to remove problematic conditions in the purchase agreement to procure the key HIV prevention drug cabotegravir long-acting (CAB-LA). These last-minute additions by ViiV to the purchase agreement included a confidentiality clause akin to a Non-Disclosure Agreement (NDA) on the drug’s price and supply; and conditions undermining supply security in which ViiV retains the power to terminate the contract or refuse the purchase order without just reasons.
